Research Terms
This production of highly concentrated and potent Adeno-Associated Virus (AAV) vectors has significant advantage over available protocol and allows for large-scale manufacturing of the virus. More than 6 percent of all gene therapy clinical trials worldwide use AAV vectors due to their ability to transfer genetic material to non-dividing cells and apparent lack of a human immune response. Unfortunately, AAV vectors are expensive because they only can be manufactured in small batches. University of Florida researchers have used a suspension format to produce high quality AAV vectors that are significantly more potent than existing vectors and allow for large-scale manufacturing.
Large-scale production of highly potent AAV vectors
AAV vectors are typically produced using transfection or infection on an adherent flat platform, which limits scale-up manufacturing. By changing this protocol, University of Florida researchers were able to produce a higher yield of a more potent vector particle in a format suitable to scale up, both for research and commercial goals.
This production of adeno-associated viral vectors using sodium chloride and potassium chloride mediate increases yields of highly infectious viral vectors up to 10-fold as compared to other production methods. The global viral vector manufacturing market is projected to reach $815.8 million by 2023. In particular, AAV vectors have clinical and research applications, including use in FDA-approved gene therapy drugs, because they allow for long-term gene expression. However, widespread clinical use of AAV vectors has been limited due to production bottlenecks and failure to meet the manufacturing demands required for clinical trials.
Researchers at the University of Florida have developed a production system that generates high yields of AAV viral vectors. This system has demonstrated increased yields up to 10-fold as compared to other production methods, offering a potential solution to low-performing production systems that have limited the clinical use of AAV vectors for gene therapy.
High-yield AAV vector production system that provides a scalable solution for high-titer and high-quality vectors using the herpes simplex virus platform
This high-yield AAV vector production system is scalable and can increase yields up to 10-fold as compared to other production systems. This system increases yields and infectivity of AAV vectors in mammalian cells by manipulating the concentrations of potassium and sodium chloride in the production medium. The salt concentrations can be altered before, during, or after mammalian cells make contact with a viral vector such as the herpes simplex virus.
1200 NEWELL DRIVE ACADEMIC RESEARCH BUILDING RG-187 PO BOX 100296 GAINESVILLE, FL 32610-3012